Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cartesian Therapeutics, Inc.SELB · Entity 6015 | Director · President and CEO | November 13, 2017 | November 15, 2017 |
| Traws Pharma, Inc.TRAW · Entity 8032 | Director | July 09, 2026 | July 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cartesian Therapeutics, Inc.
Report date November 13, 2017 · Filed November 15, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 321,203 |
Reported balance
After 2017-11-13 transaction · row 1
1 source rowRow 1 · 2017-11-13 · Purchase · Acquired 20,000 · Balance 321,203 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.20 to $9.50, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) of this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.20 to $9.50, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) of this Form 4.
Traws Pharma, Inc.
Report date July 09, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.68 · Expires 2036-07-09 | Direct | 14,150 |
Reported balance
After 2026-07-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-09 · Grant · Acquired 14,150 · Balance 14,150 F1: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2026 Filed Jul 16, 2026 01:32 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to buy) · Derivative | 14,150 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0001237419-26-000003 · form4-07162026_010736.xml · derivative · entry 1 CAUTREELS WERNER · CIK 0001237419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,150 Underlying: Common Stock · 14,150 shares Expires 2036-07-09 F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. Read SEC document |
| March 08, 2026 Filed Mar 10, 2026 23:21 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to buy) · Derivative | 31,258 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001237419-26-000002 · form4-03102026_110356.xml · derivative · entry 1 CAUTREELS WERNER · CIK 0001237419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,258 Underlying: Common Stock · 31,258 shares Expires 2036-03-08 F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 23:21 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 19,496 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001237419-25-000004 · form4-12162025_111247.xml · derivative · entry 2 CAUTREELS WERNER · CIK 0001237419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,496 Underlying: Common Stock · 19,496 shares Expires 2035-12-12 F2 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 23:21 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantCommon Stock | 4,874 | $0.00 | $0.00 |
DisclosureSEC source: 0001237419-25-000004 · form4-12162025_111247.xml · nonDerivative · entry 1 CAUTREELS WERNER · CIK 0001237419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,222 F1 · shares: Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis. Read SEC document |
| October 12, 2025 Filed Oct 16, 2025 00:06 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 11,530 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001237419-25-000003 · form4-10162025_121028.xml · derivative · entry 1 CAUTREELS WERNER · CIK 0001237419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,530 Underlying: Common Stock · 11,530 shares Expires 2035-10-12 F1 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date. Read SEC document |
| June 19, 2025 Filed Jun 23, 2025 21:50 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 23,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001415889-25-017992 · form4-06232025_090600.xml · derivative · entry 1 CAUTREELS WERNER · CIK 0001237419 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2035-06-19 F1 · derivative.exercise_date: These options vest 100% on the first anniversary of the grant date. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 23:23 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | Exercise / conversionPre-Funded Warrant (right to buy) · Derivative | 96,348 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001415889-25-004727 · form4-02192025_110231.xml · derivative · entry 2 CAUTREELS WERNER · CIK 0001237419 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,348 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The Pre-Funded Warrants became exercisable upon stockholder approval on February 17, 2025. F3 · derivative.expiration_date: The Pre-Funded Warrants do not expire. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 23:23 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | Exercise / conversionCommon Stock | 96,348 | $0.01 | $963.48 |
DisclosureSEC source: 0001415889-25-004727 · form4-02192025_110231.xml · nonDerivative · entry 1 CAUTREELS WERNER · CIK 0001237419 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Common Stock was acquired by way of an exercise of Pre-Funded Warrants at an exercise price of $0.01 per Pre-Funded Warrant. The Pre-Funded warrants were acquired as part of Class B Units, with each Class B unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit. Read SEC document |
| December 29, 2024 Filed Jan 28, 2025 00:02 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | PurchaseSeries A Warrant (right to buy) · Derivative | 96,348 | Not disclosed Strike: $13.42 | Not disclosed |
DisclosureSEC source: 0001104659-25-006408 · tm254427-3_4seq1.xml · derivative · entry 2 CAUTREELS WERNER · CIK 0001237419 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,348 Underlying: Common Stock · 96,348 shares Expires not disclosed F3 · price: The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit. F4 · derivative.exercise_date: The Series A Warrants shall become exercisable on June 30, 2025; provided however, that the Series A Warrants may not be exercised prior to the issuer's receipt of stockholder approval of the exercise of the Series A Warrants, in accordance with Nasdaq listing rules. F5 · derivative.expiration_date: The Series A Warrants shall expire on the date that is the earlier of (a) December 31, 2029, and (b) subject to the fulfilment of certain equity conditions, thirty trading days after the last of the following data readouts to occur, as announced by the issuer: (i) Ferret animal model Bird Flu data, (ii) non-human primate Bird Flu data, or (iii) Phase 2a Influenza A human clinical data. Read SEC document |
| December 29, 2024 Filed Jan 28, 2025 00:02 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | PurchasePre-Funded Warrant (right to buy) · Derivative | 96,348 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0001104659-25-006408 · tm254427-3_4seq1.xml · derivative · entry 1 CAUTREELS WERNER · CIK 0001237419 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,348 Underlying: Common Stock · 96,348 shares Expires not disclosed F3 · price: The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit. F1 · derivative.exercise_date: The Pre-Funded Warrants shall become exercisable upon stockholder approval of the exercise of the Pre-Funded Warrants, in accordance with Nasdaq listing rules. F2 · derivative.expiration_date: The Pre-Funded Warrants do not expire. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:03 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | GrantCommon Stock | 200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000929638-24-001362 · form4.xml · nonDerivative · entry 1 CAUTREELS WERNER · CIK 0001237419 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 F1 · price: Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025. Each restricted stock unit will convert into common stock of Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc.), par value $0.01 per share, on a one-for-one basis. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 02:57 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | PurchaseCommon Stock | 20,000 | $9.31 | $186,250.00 |
DisclosureSEC source: 0001638599-17-001135 · doc4_5078.xml · nonDerivative · entry 1 CAUTREELS WERNER · CIK 0001237419 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,203 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.20 to $9.50, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) of this Form 4. Read SEC document |
| July 07, 2017 Filed Jul 11, 2017 20:44 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $19.33 | $0.00 |
DisclosureSEC source: 0001638599-17-000700 · doc4_4843.xml · derivative · entry 1 CAUTREELS WERNER · CIK 0001237419 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-07-06 F1 · derivative.exercise_date: This option vests as to 25% of the shares on June 16, 2018. The remainder of the shares will vest in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.